News of Note—Johnson & Johnson, Bavarian Nordic and more | FiercePharma
Skip to main content

News of Note—Johnson & Johnson, Bavarian Nordic and more

In this week's news of note, Johnson & Johnson announced a data publication for its "mosaic-based" HIV vaccine. (Pixabay)

Here is some other vaccine news of note for the week:

> Johnson & Johnson announced that The Lancet published data from its phase 1/2b study of a "mosaic-based" HIV vaccine. The company advanced the shot to an efficacy test last November. Release | FiercePharma article

> Bavarian Nordic announced that a phase 2 trial of the company's cancer vaccine CV301 and Bristol-Myers Squibb's Opdivo started in patients with resectable hepatic-limited metastatic colorectal cancer. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> MabVax licensed an antibody development program for multiple cancers to Boehringer Ingelheim for $11 million upfront, plus undisclosed milestones. Release

> Even though Neovacs' therapeutic lupus vaccine missed a primary efficacy endpoint in a phase 2b study, the company is moving into phase 3 based on other results. Release

> Altimmune named Mitchel Sayare, Ph.D., its executive chairman and José Ochoa its chief business officer. Release

Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.